Benign Prostatic Hyperplasia and Antimuscarinic Treatment

Objective & Hypothesis:The term lower tract urinary symptoms (LUTS) has been replacing the terms such as prostatism, symptomatic benign prostatic hyperplasia (BPH), and clinical BPH used in the evaluation of male patients with symptoms associated with the urinary system.

📊

Key Findings & Data:Today the standard and most common medical treatment for BPH is the use ?1- adrenergic receptor blockers.

💡

Conclusion & Impact:This paper reviews the effectiveness and safety of the use of antimuscarinic treatments in patients with BPH

🔬Design:Review & Systematic Survey

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

The term lower tract urinary symptoms (LUTS) has been replacing the terms such as prostatism, symptomatic benign prostatic hyperplasia (BPH), and clinical BPH used in the evaluation of male patients with symptoms associated with the urinary system. Many health conditions including BPH, overactive bladder (OAB), nocturnal polyuria, urinary tract infections, distal ureteral calculi, and bladder tumors can cause LUTS. The symptoms covered by the commonly used term LUTS are categorized into three subgroups; those associated with storage, those associated with urination, and those seen after urination. Today the standard and most common medical treatment for BPH is the use ?1- adrenergic receptor blockers. However, the search for alternative treatment modalities continues, especially for situations in which ?1-adrenergic receptor blockers are considered as insufficient. With the relevant reports in the literature, this led to the use of antimuscarinic drugs together with the ?1-adrenergic receptor blockers as a combination therapy to treat BPH. This paper reviews the effectiveness and safety of the use of antimuscarinic treatments in patients with BPH

Özet

Alt üriner sistem semptomları (AÜSS) terimi; üriner sistem semptomlarına sahip erkek hastaları değerlendirmede kullanılan prostatizm, semptomatik benign prostat hiperplazisi (BPH) ve klinik BPH terimlerinin yerini almaktadır. BPH, aşırı aktif mesane (AAM), nokturnal poliüri, üriner sistem enfeksiyonları, distal üreter taşları ve mesane tümörleri gibi birçok sağlık sorunu AÜSS'ye neden olabilir. Yaygın kullanılan bir terim olan AÜSS kapsamına giren semptomlar; depolama (acil idrar yapma hissi, sık idrara çıkma, gece idrar yapmak için uyanma ve urge inkontinans), işeme (işeme gücünde azalma, idrarı başlatmakta gecikme, kesik kesik idrar yapma) ve işeme sonrası (işeme sonrası damlama, yetersiz boşaltım hissi) ile ilgili semptomlar olarak üç alt grupta toplanmıştır. Günümüzde BPH için uygulanan en yaygın ve standart tıbbi tedavide ?1-adrenerjik reseptör antagonistleri kullanılmaktadır. Bu tedavinin yetersiz kaldığı düşünülen durumlar için alternatif tedavi arayışları halen sürmektedir. Bu çalışmalar sonucunda, BPH'nin tedavisinde ?1blokerler ile birlikte kullanılan antimuskarinik ilaçlar, bir kombine tedavi olarak literatürdeki yerini almıştır. Bu derlemede; BPH'den muzdarip hastalarda antimuskarinik tedavilerinin etkinliği ve güvenilirliği değerlendirilmiştir

🔖

Cite This Article

KAYNAR, M., GÖKTAŞ, S., ALTINTAŞ, E. (2022). Benign Prostatic Hyperplasia and Antimuscarinic Treatment. Anadolu Kliniği Tıp Bilimleri Dergisi, Cilt: 21 - Sayı: 2, 163–169. https://ajindex.com/articles/437783

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (12)

Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, et al. EAU guidelines on the tre- atment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obs- truction. Eur Urol. 2013;64(1):118-40.
Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulm- sten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167-78.
Kaplan SA, Bowers DL, Te AE, Olsson CA. Differential diagnosis of prostatism: a 12-year retrospective analysis of symptoms, urodynamics and satisfaction with the- rapy. J Urol. 1996;155(4):1305-8.
Hyman MJ, Groutz A, Blaivas JG. Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol. 2001;166(2):550-2.
Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. National community prevalence of overacti- ve bladder in the United States stratified by sex and age. Urology. 2011;77(5):1081-7.
Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lo- wer urinary tract symptoms in men: focus on the blad- der. Eur Urol. 2006;49(4):651-9.
Chess-Williams R, Chapple CR, Yamanishi T, Yasuda K, Sellers DJ. The minor population of M3-receptors me- diate contraction of human detrusor muscle in vitro. J Auton Pharmacol. 2001;(5-6) 21:243-8.
Matsui M, Motomura D, Karasawa H, Fujikawa T, Jiang J, Komiya Y, et al. Multiple functional defects in periphe- ral autonomic organs in mice lacking muscarinic acetyl- choline receptor gene for the M3 subtype. Proc Natl Acad Sci USA. 2000;97(17):9579-84.
Abrams P, Kaplan S, De Koning Gans HJ, Millard R. Sa- fety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstructi- on. J Urol. 2006;175(3):999-1004.
Kaplan SA, Walmsley K, Te AE. Tolterodine exten- ded release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol. 2005;174(6):2273-5.
Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006; 296(19):2319-28.
Roehrborn CG, Kaplan SA, Kraus SR, Wang JT, Ba- vendam T, Guan Z. Effects of serum PSA on efficacy of tolterodine extended release with or without tam- sulosin in men with LUTS, including